GSC The List

Post Reply
Forum Home > S > SPASTICITY*+

[email protected]
Site Owner
Posts: 1174

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids (full - 2010)

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis (abst – 2010)

Role of cannabinoids in the treatment of pain and (painful) spasticity. (abst – 2010)

Dronabinol for the treatment of unspecific pain, restlessness and spasticity in neuropaediatrics (abst – 2010)

Emerging treatment options for spasticity in multiple sclerosis; clinical utility of cannabinoids (link to PDF – 2011)

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis (abst – 2011)

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (abst - 2011)

Cannabinoids in children (abst – 2011)

The Therapeutic Potential of Cannabis and Cannabinoids (full – 2012)

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols) (full – 2012)

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. (full – 2012)

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial (full – 2012)

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity (full – 2012)

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (abst – 2012)

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis (abst – 2012)

What place for cannabis extract in MS? (abst – 2012)

Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids (abst – 2012)

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis. (abst – 2012)

Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids (abst – 2012)

Smoked Cannabis Reduces Some Symptoms of Multiple Sclerosis (news – 2012)

Cannabis as Painkiller (news – 2012)

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis (full – 2013)

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain (abst – 2013)

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report (abst – 2013)

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany (abst – 2013)

Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors (abst – 2013)

Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists (abst – 2013)

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis (abst – 2013)

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice (abst – 2013)

Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience (full – 2014)

THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies (full – 2014)

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis related spasticity. (abst – 2014)

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity (abst – 2014)

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis (abst – 2014)

Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice (abst – 2014)

Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis. (abst – 2014)

Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users. (abst – 2014)

Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways. (abst – 2014)

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis (abst – 2014)

There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis (abst – 2014)

Complementary and alternative medical therapies in multiple sclerosis-the american academy of neurology guidelines: a commentary (abst – 2014)

"Disease Modifying Nutricals" for multiple sclerosis (abst – 2014)

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation (full – 2015)

Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability (full – 2015)

March 28, 2015 at 6:22 AM Flag Quote & Reply

This topic is closed, no additional posts are allowed.